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Abstract
Hepatoid adenocarcinoma is an extrahepatic tumor characterized by morphological similarities to
hepatocellular carcinoma. Hepatoid adenocarcinoma of the stomach is a cancer with an extremely
poor prognosis with few cases reported. Here, we describe a 75-year-old Spanish man referred to
our hospital with a history of abdominal pain, general fatigue, anorexia and sickness. Initial study
revealed anemia, and computed tomography scan and abdominal ultrasonography showed multiple
metastases to the liver with hepatocellular carcinoma characteristics in a liver with no cirrhotic
change. Further study included a serum level of alpha-fetoprotein (AFP), which resulted markedly
elevated, and a conclusive esophagogastroduodenoscopy describing an elevated tumour growing
through the cardia and gastroesophageal junction with foci of necrosis and haemorrhage. Gastric
biopsies of the tumor revealed poorly differenciated adenocarcinoma, with hepatoid differentiation.
After a diagnosis of AFP-producing hepatoid adenocarcinoma of the stomach with multiple liver
metastases was made, pallitive total gastrectomy, without liver resection, was performed. Patient
recovered well after surgery, and entered into a palliative systemich chemotherapy protocol.
Although this illness is recognized as having poor prognosis, the patient remains alive 8 months
after the operation. Accurate diagnosis of hepatoid adenocarcinoma of the stomach is important,
and should be suspected under certain circumstances. We describe this rare case of hepatoid
adenocarcinoma of the stomach, and review the literature concerning the clinicopathological
aspects.
Background
Alpha-fetoprotein (AFP) level in serum, initially elevated
due to fetal liver, yolk salk, and some fetal gastrointestinal
cells production, rapidly decreases after birth [1]. AFP
level is, however, elevated in patients with hepatocellular
carcinoma and in those with other liver diseases associ-
ated with liver regeneration [2-4]. AFP-producing tumors,
others than hepatocellular carcinoma, have been
described [5-8]. First reported in 1970 by Bourreille et al.
[10], AFP-producing gastric adenocarcinoma has now an
incidence reported to be 1.3% – 15% of all gastric carcino-
mas [11,12]. In 1981, Kodama et al. described two histo-
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logic types of AFP-producing gastric carcinoma with
medullary or papillotubular arrangements [13]. Later
Ishikura et al. [14,15] proposed the term "hepatoid aden-
ocarcinoma of the stomach" for primary gastric carcino-
mas that are characterized by both hepatoid
differentiation and the production of large amounts of
AFP. In 1986, the clinicopathologic entity was broadened
to include gastric carcinoma showing hepatic differentia-
tion without the production of AFP. Hepatoid adenocar-
cinomas have also been reported in several different
organs, such as those occurring in the lung, pancreas and
ovary, although gastric adenocarcinoma continuous to be
one of the most commons of these tumours [5-9]. This
type of tumour is a relatively rare gastric carcinoma, and is
recognized as having poor prognosis, even if the tumour
is diagnosed at an early stage. In this report, we describe a
rare case of hepatoid adenocarcinoma of the stomach,
with a review of the literature concerning clinicopatholog-
ical aspects.
Case presentation
A 75-year-old man presented at the emergency depart-
ment of Vega Baja Hospital, Orihuela, Alicante, on Febru-
ary 2008, with of a 15-day history of abdominal pain,
general fatigue, anorexia and sickness. His medical history
included hypertension, adenomatous colonic polyposis,
upper gastrointestinal bleeding secondary to agiodyspla-
sia treated with enterectomy in 2005, obstructive pulmo-
nary chronic disease related to hemp industry, and right
adrenal adenoma since 2005.
On physical examination only paleness of skin and con-
junctiva was detected. He was referred to Internal Medi-
cine Department fur further study. Haematological
investigations revealed anemia (Hemoglobine (Hb), 7.1
g/dl; hematocrit (Ht), 25% and high levels of AFP (4,500
UI/mL) and CEA (460 ng/mL). Chest and abdominal
radiograph were negative. After blood transfussion, other
image test were performed. Abdominal ultrasonoraphy
showed liver with muliple nodules, biggest in left liver
lobe (56 × 51 mm.), highly suspicious for hepatocellular
carcinoma (Figure 1. Abdominal ultrasonoraphy showing
liver with muliple nodules, biggest in left liver lobe,56 ×
51 mm., highly suspicious for hepatocellular carcinoma).
Esophagogastroduodenoscopy findings showed an ele-
vated tumour growth through the cardia and gastro-
esophageal junction with foci of necrosis and
haemorrhage. Gastric biopsy of the gastroesophageal
junction revealed on hematoxylin eosin staining poorly
differenciated adenocarcinoma, with probably hepatoid
differentiation. The inmunohistochemical staining
showed strongly positive for AFP (Figure 2. Gastric biopsy
400×. Hemotoxylin Eosin staining) (Figure 3. Gastric
biopsy with inmunohistochemical staining showing
strongly positivity for AFP). Further inmunohistochemi-
cal analysis revealed positive expression of CDX2 and
CD10, as more than 10% of the carcinoma cells were
stained.
With definite diagnosis of AFP-producing hepatoid gastric
adenocarcinoma metastatic to the liver, patient was then
referred to Clinical Oncology Department where, in order
to complete pretreatment evaluation, a thoracic-abdomi-
nal-pelvic CAT was requested. Results of computed tom-
ography revealed multiple solid lesions suggestive of
Abdominal ultrasonoraphy showing liver with muliple nod- ules, biggest in left liver lobe (56 × 51 mm.), highly suspicious  for hepatocellular carcinoma Figure 1
Abdominal ultrasonoraphy showing liver with muli-
ple nodules, biggest in left liver lobe (56 × 51 mm.), 
highly suspicious for hepatocellular carcinoma.
Gastric biopsy 400× Figure 2
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metastases in both lobes of the liver. A thickening of the
medial wall-less curvature of the stomach and lymph
node swelling around the gastro-hepatic ligament suspi-
cious of gastric neoplasia was also described (Figure 4.
Computed tomography showing multiple solid lesions
suggestive of metastases in both lobes of the liver, and a
thickening of the medial wall-less curvature of the stom-
ach and lymph node swelling around the gastro-hepatic
ligament suspicious of gastric neoplasia).
The patient required meanwhile 6 blood transfusions
because of persistent melena and referred symptomatic
anemia so he was proposed first to palliative total gastrec-
tomy. Surgery was succesfully completed with gastric
resection including a bleeding polylobate endoluminal
mass located in the cardias and gastroesophageal junction
(Figure 5. Total gastrectomy specimen) (Figure 6. Upper
vision of opened gastrectomy specimen with tumor upper
left) (Figure 7. Lateral vision of gastrectomy specimen
showing excrecent tumor). During surgery liver metas-
tases were palpable and visible as they were in the liver
surface (Figure 8. Liver metastases were palpable and visi-
ble during surgery as they were in the liver surface), but no
surgical procedure besides palliative gastrectomy was per-
formed. Anatomopathology analysis revealed a 9 cm big
gastric hepatoid adenocarcinoma which penetrated serosa
without invasion of adjacent structures (pT3), with no
vascular invasion (V0). Regional lymph node assessment
described 9 out of 16 lymph nodes with metastasis of
hepatoid adenocarcinoma (pN2). Inmunohistoquemical
analysis of the resected tumor was negative for CK7, CD
20, and cromogranine, while positive for CEA and AFP.
Patient soon recovered after surgery with no major com-
plications besides requiring percutaneous drainage of
subfrenic collection in the seventh day postoperative.
Total Hospital stay for surgical procedure and manage-
ment of subfrenic collection was of sixteen days. Patient
was then referred again to Clinical Oncology Department.
By that time patient complained for anorexia and gas-
Gastric biopsy with inmunohistochemical staining showing  strongly positivity for AFP Figure 3
Gastric biopsy with inmunohistochemical staining 
showing strongly positivity for AFP.
Computed tomography showing multiple solid lesions sug- gestive of metastases in both lobes of the liver, and a thicken- ing of the medial wall-less curvature of the stomach and  lymph node swelling around the gastro-hepatic ligament sus- picious of gastric neoplasia Figure 4
Computed tomography showing multiple solid 
lesions suggestive of metastases in both lobes of the 
liver, and a thickening of the medial wall-less curva-
ture of the stomach and lymph node swelling around 
the gastro-hepatic ligament suspicious of gastric neo-
plasia.
Total gastrectomy specimen Figure 5
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trointestinal disorders supposedly related to recent sur-
gery. He had lost eight kilograms since first admission
into hospital 30 days before. As his karnofsky score was
70, with no major hematological or chemistry abnormal-
ities, palliative chemotherapy consisting of cisplatin and
capecitabine was advised. Patient since then has received
six cycles of chemotherapy with stable disease on CAT and
progressive reduction of AFP and CEA values on evalua-
tion after third and sixth cycles. Tolerance to chemother-
apy has been adequate with grade II hand-foot syndrome,
grade II nausea, grade I diarrhea as most relevant toxici-
ties, with no grade 3/4 toxicities reported. Further chemo-
therapy with the same cisplatin and capecitabine regimen
is being administered.
Discussion
Gastric hepatoid adenocarcinoma is a kind of tumour
with unique histological characteristics. Although it has
been reported in the lung, pancreas, uterus and ovary, it is
most commonly seen in the stomach [5-9]. It is consid-
ered an AFP- producing malignant tumour. Kodoma et al.
[12] described two histologic types of AFP-producing gas-
tric carcinoma, based on inmunohistochemical staining; a
medullary type, characterized by polygonal cells arranged
in solid nest or sheets, with scattered large pleomorphic or
multinucleated giant cells, and well differenciated papil-
lary or tubular type with clear cytoplasm. The two types
sometimes coexisted in a single tumour. The reported
incidence of AFP-producing gastric carcinoma has been
1.3%–15% of all gastric carcinomas [11,12].
Why some gastric carcinomas show hepatoid differentia-
tion and produce AFP has been the subject of some
debate. Ishikura et al. [14,15] suggested that this may be
due to the fact that the stomach and liver are both derived
from primitive foregut of the embryo. Because of this, dis-
turbances of differentiation ultimately may result in the
development of foci of hepatocellular differentiation. Fur-
thermore, there is sometimes confusion about whether
hepatoid carcinoma originates from the stomach or the
liver, because most patients show multiple liver metasta-
sis preoperatively [16].
Hepatoid carcinoma contains a tubular adenocarcinoma
that seems to develop "hepatoid features", but the relation
between the tubular adenocarcinomatous and the
hepatoid components remains unclear. A recent analysis
from Kumashiro et al. [17] compared the cellular peno-
types of 23 cases of hepatoid adenocarcinoma of the
Upper vision of opened gastrectomy specimen with tumor  upper left Figure 6
Upper vision of opened gastrectomy specimen with 
tumor upper left.
Lateral vision of gastrectomy specimen showing excrecent  tumor) Figure 7
Lateral vision of gastrectomy specimen showing 
excrecent tumor).
Liver metastases were palpable and visible during surgery as  they were in the liver surface) Figure 8
Liver metastases were palpable and visible during 
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stomach having tubular adenocarcinomatous compo-
nents with 69 cases of non-hepatoid adenocarcinoma of
the stomach. Four phenotypic categories according to the
inmunohistochemical results for CD10, MUC2,
MUC5AC, and MUC6 were described for both compo-
nents, tubular adenocarcinomatous and hepatoid, of
hepatoid adenocarcinoma. The complete intestinal phe-
notype (CD10+, MUC5AC-, MUC6-), such is the case for
our patient, was most frequently observed in the adeno-
carcinomatous and hepatoid components (61 and 65%,
respectively). In contrast, no gastric phenotype
(MUC5AC+, MUC6+, MUC2-, CD10-) was observed in
any of the hepatoid adenocarcinoma components. The
fact that positivity for CDX2 was predominant in all the
adenocarcinomatous components, while negative in 39%
of the hepatoid components, suggests that hepatoid ade-
nocarcinoma arises from an adenocarcinoma with intesti-
nal phenotype and that its hepatoid component is in
some way related to reduced CDX2 expressión.
Case reports of "hepatoid adenocarcinoma of the stom-
ach" have been previously reported in the literature. In
2001, Inawaga et al. [16] revised all these cases and pub-
lished a report with the main clinical characteristics of
these kind of tumours. They concluded that the majority
of patients were male and the average age was about 64
years old. The antrum and pylorus are the common pri-
mary sites of tumour and there were AFP levels much
higher than normal. Although there were no major symp-
toms sufficient to allow diagnosis of this type of cancer,
epigastric pain and general fatigue, because of anaemia,
were the most common symptoms. Most cases also had
metastatic disease to the lymph nodes or liver. Data sug-
gest than even early-stage hepatoid adenocarcinoma has
an extremely poor prognosis.
Nowadays, the reasons for the poor prognosis are not
clearly understood. One possibility is that hepatoid aden-
ocarcinoma produces AAT (alpha-1 antitrypsin) and/or
ACT (alpha-1 antichymotripsin) as well as AFP. AAT and
ACT have immunosuppressive and protease-inhibitory
properties that enhance invasiveness [16,17]. Also, AFP
has a suppressive effect on lymphocyte transformation.
Furthermore, these tumours are known to be resistant to
chemotherapy [16,18].
The efficacy of palliative gastrectomy in patients with
incurable advanced gastric cancer remains debatable. Pre-
vious reports suggested that palliative gastrectomy might
be beneficial for younger patients (aged under 70 years)
with one mestastatic site [19], while other clinicians
argued that the survival advantage of palliative gastrec-
tomy could be confirmed if the tumor spread was
restricted to one site [20]. Another report showed that pal-
liative gastrectomy combined with systemic chemother-
apy improved survival in a group of patients with stage IV
tumors [21]. While most of the studies published so far
qualified the extent of the advanced gastric cancer, and
found a survival benefit after resection if the number of
metastatic sites of spread was limited to one or two [20-
25], the literature is divided regarding the effect of resec-
tion on quality of life [26]. The presence of metastatic
hepatoid adenocarcinoma of the stomach discovered at
surgery may pose problems in surgical decision-making.
There is a question as to whether liver involvement is sec-
ondary to the primary tumor of the stomach or the stom-
ach involvement secondary to the primary tumor of the
liver [27]. In patients in satisfactory general condition,
with metastatic hepatoid adenocarcinoma of the stomach
to the liver, whether diagnosed preoperatively or at sur-
gery, we believe the stomach tumor should be resected if
feasible for palliation.
Palliative chemotherapy should be advised to all patients
with advanced gastric cancer and good performance sta-
tus. Analysis of results of trials carried out until 2003 on
this topic showed chemotherapy to be superior to best
supportive care alone. Combination chemotherapy com-
pared with monochemotherapy was also associated with
significantly higher overall (complete plus partial)
response rates but nevertheless resulted in similar sur-
vival. Cisplatin and 5-fluorouracil combination with or
without epirrubicin used by then to represent the most
effective regimens for advanced gastric cancer [28]. New
combination regimens incorporating chemotherapeutic
agents such as docetaxel, irinotecan, capecitabine and
oxaliplatin have broadened perspectives for patients in
terms of response rates, progression free and overall sur-
vival, and quality of life [29-32]. Capecitabine is an oral
fluoropyrimidine already approved for colorrectal and
breast cancer treatment which has been recently approved
for the treatment of advanced gastric cancer in combina-
tion with a cisplatin containing regimen. The approval is
based on the results of two randomised trials which dem-
onstrated non-inferiority of capecitabine as compared to
continuous infusion of fluorouracil in terms of overall
survival, progression free survival, as well as of response
rates [31,32]. In addition, by substituting flurorouracil for
capecitabine, convenience of an oral treatment, and
avoidance of possible complications and drawbacks
related to continuous infusion are offered to the patients,
with consequently gain in quality of life.
In conclusion, we report a case hepatoid adenocarcinoma
of the stomach, a relatively rare entity, with well defined
clinicopathological features, and usually associated to rec-
ognized poor prognosis, in which the realisation of palli-
ative surgery and the administration of novel palliative
systemic chemotherapy may have had major impact on
survival.International Seminars in Surgical Oncology 2009, 6:13 http://www.issoonline.com/content/6/1/13
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